BE.Amycon Biobank & Data Registry UZ Leuven

Abroad (travel likely)Recruiting

Conditions

Amyloidosis · AL Amyloidosis · Amyloidosis Cardiac

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UZ Leuven Gasthuisberg - hematology, Leuven, Belgium
Contact: Study coordinator (Michel Delforge, Prof.)
UZ Leuven Gasthuisberg - cardiology, Leuven, Belgium
Contact: Study coordinator (Lucas Van Aelst, Prof.) · +32 16344263

Study leads

Michel Delforge
Principal Investigator
UZ Leuven Gasthuisberg
Joost Schymkowitz, Prof.
Principal Investigator
VIB - Switch Lab
Frederic Rousseau, Prof.
Principal Investigator
VIB - Switch Lab

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies

Abroad (travel likely)RecruitingPHASE2

Chandler, United States · Scottsdale, United States

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis · Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nashville, United States · Dallas, United States

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Amyloidosis

Abroad (travel likely)RecruitingPHASE3

Beijing, China

Institutional Registry of Rare Diseases

Rare Diseases · Amyloidosis · Sarcoidosis

Abroad (travel likely)Recruiting

Buenos Aires, Argentina